Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue.

MLA

Dixon, Eric P., et al. “Characterization and Clinical Validation of MCM2 and TOP2A Monoclonal Antibodies in the BD ProEx™ C Assay: An Immunoassay Which Detects Aberrant S-Phase Induction in Cervical Tissue.” Journal of Immunological Methods, vol. 442, Mar. 2017, pp. 35–41. EBSCOhost, https://doi.org/10.1016/j.jim.2017.01.002.

APA

Dixon, E. P., King, L. M., Nelson, R., Simkins, S. G., Knapp, S. L., Brough, G. H., Lenz, K. L., Henderson, D. T., Whitehead, C. M., Hessling, J., Brown, C. A., & Malinowski, D. P. (2017). Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue. Journal of Immunological Methods, 442, 35–41. https://doi.org/10.1016/j.jim.2017.01.002

Chicago

Dixon, Eric P, Lorraine M King, Ramona Nelson, Stephen G Simkins, Steven L Knapp, George H Brough, Karen L Lenz, et al. 2017. “Characterization and Clinical Validation of MCM2 and TOP2A Monoclonal Antibodies in the BD ProEx™ C Assay: An Immunoassay Which Detects Aberrant S-Phase Induction in Cervical Tissue.” Journal of Immunological Methods 442 (March): 35–41. doi:10.1016/j.jim.2017.01.002.